Alchemab Therapeutics is a biotechnology company focused on harnessing the power of the immune system to develop novel antibody therapeutics for hard-to-treat diseases. Their unique platform identifies naturally occurring protective antibodies from resilient individuals, such as long-term cancer survivors, using advanced deep learning and B cell sequencing techniques. With a strong emphasis on neurodegenerative conditions and oncology, Alchemab is building a diverse pipeline of therapeutics, supported by collaborations with patient groups and academic institutions. The company aims to transform drug discovery by leveraging insights from the immune system to create effective treatments for challenging diseases.

Beam Therapeutics will manufacture precision genetic medicines through the use of base editing technology at its RTP site.

Carbon Biosciences develops genetic medicines for the treatment of devastating diseases. They develop their vector using industrial-scale viral production platforms and can be used to deliver a wide-range of therapeutic modalities.

Ceribell is revolutionizing electroencephalography (EEG) by providing a point-of-care EEG system that is FDA cleared and designed for rapid deployment in emergency and critical care settings. Their innovative technology allows healthcare providers to set up the EEG system in just six minutes, enabling faster diagnosis and treatment of seizures, including non-convulsive seizures. The proprietary Brain Stethoscope function simplifies EEG interpretation by converting brainwaves into sound, making it accessible for non-specialists. This approach not only improves patient outcomes but also reduces mortality and complications associated with delayed diagnosis. Ceribell's focus on efficiency and accessibility positions it strongly in the healthcare market, particularly in intensive care units and emergency departments.

Certik is a pioneer in blockchain security, leveraging best-in-class AI technology to protect and monitor blockchain protocols and smart contracts. Founded in 2018 by professors from Yale University and Columbia University, Certik’s mission is to secure the Web3 world. Certik applies cutting-edge innovations from academia to enterprise, enabling mission-critical applications to scale with safety and correctness. One of the fastest-growing and most trusted companies in blockchain security, Certik is a true market leader. To date, Certik has worked with nearly 4,000 enterprise clients, secured over $360 billion worth of digital assets, and has detected nearly 70,000 vulnerabilities in blockchain code. Our clients include leading projects such as Aave, Polygon, Binance Smart Chain, Terra, Yearn, and Chiliz. Certik is backed by Insight Partners, Sequoia, Tiger Global, Coatue Management, Lightspeed, Advent International, SoftBank, Hillhouse Capital, Goldman Sachs, and Coinbase Ventures.

CG Oncology is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. Their product candidate, cretostimogene grenadenorepvec, is an investigational engineered oncolytic immunotherapy that has shown clinical benefit in BCG-unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC). The company aims to provide innovative therapies that enhance the quality of life for urologic cancer patients, positioning itself as a leader in the bladder cancer treatment market with a strong focus on patient-centered care and ongoing clinical trials.

Cobo is a trusted leader in digital asset custody and wallet infrastructure solutions. Founded in 2017 by blockchain pioneers, Cobo is trusted by more than 500 organizations worldwide, safeguarding billions of dollars in assets with a zero-incident security track record. Today, Cobo provides the industry’s only unified digital asset wallet platform that integrates all 4 wallet technologies in one place – custodial wallets, MPC wallets, smart contract wallets, and exchange wallets. By combining a comprehensive suite of wallet solutions with advanced risk controls and developer tools, Cobo empowers organizations and developers to innovate and scale with ease.

Cosmos is an ever-expanding ecosystem of interoperable and sovereign blockchain apps and services, built for a decentralized future.

Darmiyan is a pioneering company focused on brain health, utilizing advanced AI and medical imaging to detect neurodegenerative diseases like Alzheimer's at early stages. Their flagship product, Brain See, is FDA-approved and combines MRI data with cognitive assessments to provide a prognosis score for patients with mild cognitive impairment. The technology is built on over 40 years of neuroscience research and aims to revolutionize brain health diagnostics and monitoring, making it accessible and non-invasive for patients and healthcare providers alike. With a strong emphasis on accuracy and integration, Darmiyan is positioned to significantly impact the healthcare landscape for brain diseases.

The DFINITY Foundation’s mission is to build, promote, and maintain the Internet Computer — the world’s first web-speed, internet-scale public blockchain. It enables smart contracts to securely serve interactive web content directly into the browsers of end users, making it possible to build dApps, DeFi, open internet services, and enterprise systems that are capable of operating at hyperscale. The Internet Computer uses smart contracts to power an emerging decentralized ecosystem of interoperable dApps and services, where nearly every system and service can run in reimagined form on public blockchain.

Engine Biosciences is a venture-backed San Francisco- and Asia-based technology company pioneering network biomedicine. Our proprietary and patented technologies oriented around deciphering the complexity of biology networks include both high-throughput wet lab experimentation and artificial intelligence algorithms for drug discovery and cellular reprogramming. This platform, developed through several years of research by our scientific founding and leadership team who include faculty members at MIT, Harvard, Mayo Clinic, and UCSD, dramatically accelerates and reduces costs of the R&D process for new medical therapies. We are actively applying the platform internally and with partners across a range of disease indications. In January 2018, we announced the closing of a US$10M seed round from notable biotech and tech institutional investors and are expanding the team.

Our passion is to provide Web3 changemakers with the ultimate infrastructure platform to reshape the world.